<img height="1" width="1" style="display:none;" alt="" src="https://dc.ads.linkedin.com/collect/?pid=412980&amp;fmt=gif">

    Cancer Theranostic Company

    OncoDNA’s mission is to provide better characterization of the patient’s cancer and hence better treatment choice and follow-up. OncoDNA’s goal is to predict and monitor the response to anticancer drugs
    using a comprehensive integrated approach (genomics combined with molecular pathology) thus enabling oncologists to make the right therapeutic decisions and determine treatment regimens.

    OncoDNA currently proposes four analyses to oncologists: OncoDEEP®, OncoSTRAT&GO®, OncoTRACE™ and OncoSELECT® (all ISO15189 compliant and CE-IVD marked).

    A report presenting the analysis results and a collection of follow-up data are available on the OncoSHARE® platform. For institutions performing their own laboratory analyses, OncoDNA also has an online, innovative analysis platform,
    OncoKDM®, to help biologists integrate all the test results from one cancer sample into a custom report. The report is then shared with oncologists to guide them in their choice of the therapy options most appropriate for each patient.